Ev3 Atherectomy Biz Stabilizing After Sales Force Improvements, Firm Says
This article was originally published in The Gray Sheet
Executive Summary
Ev3 believes a sales force restructuring initiated earlier this year is bearing fruit for its struggling atherectomy business
You may also be interested in...
ev3 Expands Neurovascular Division With Acquisition Of Chestnut
ev3 is expanding its neurovascular division, already the fastest-growing segment of the company, by buying Chestnut Medical Technologies for $75 million up-front and up to $75 million in milestone payments, the companies announced June 2
Ev3’s Atherectomy Business On The Upswing After Troubled First Quarter
Endovascular device firm ev3's formerly rocky marriage with FoxHollow is now on steadier ground with a better-than-expected recovery of its atherectomy business in the second quarter
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.